← Leaderboards
Joshua Kellogg
University Of North Carolina Greensboro
$550,783
Attributed
$550,783
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $250K · FY2018–23$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$550,783 · 2
By mechanism
R21$489,609 · 1
F32$61,174 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Greensboro
Same institution · by research overlap
- Tetyana Ignatova$36,000
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsInflammationMedicineBotanicalsEvaluationCombined Modality TherapyInfectionIn VitroNatural ProductsPreparationInnovationAntiviral AgentsCytotoxicCovid-19 PandemicCountryCoronavirusCovid-19DangerousnessBaseCessation Of LifeAnti-Inflammatory AgentsAntimalarialsBioinformaticsClinical Research
Grant awards (3)
Evaluation of Artemisia as an Effective Combination Therapy Against SARS-CoV-2 Infection$250,023
R21 · FY2023 · AI · contact PI
Evaluation of Artemisia as an Effective Combination Therapy Against SARS-CoV-2 Infection$239,586
R21 · FY2022 · AI · contact PI
The Whole is Greater than the Sum of its Parts: Identifying Active Mixture Components, and Evaluating their Combined Efficacy$61,174
F32 · FY2018 · AT · contact PI